Business
Relmada Therapeutics to Report Second Quarter 2023 Financial Results and Host Conference Call and Webcast on August 8, 2023
CORAL GABLES, Fla., Aug. 1, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the
About this update from Relmada Therapeutics, Inc.
[{"type":"text","content":"CORAL GABLES, Fla., Aug. 1, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that it will report its financial results for the second quarter ended June 30, 2023 after the market close on Tuesday, August 8, 2023. The company will host a corporate update conference call and live audio webcast at 4:30 p.m. Eastern Time on Tuesday, August 8, 2023.\n\n \n \n \n \n \n \n\n \nLive Conference Call & Webcast:\nToll Free: \n877-407-0792\nInternational: \n201-689-8263\nConference ID: \n13740070\nWebcast:\nhttps://viavid.webcasts.com/starthere.jsp?ei=1624681&tp_key=1f9f03a8ac \nA replay of the webcast will be available in the Investors section of the Relmada website at https://www.relmada.com/investors/ir-calendar.\nAbout REL-1017\nREL-1017, a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission, is currently in late-stage development for the adjunctive treatment of major depressive disorder (MDD). The ongoing Clinical Research Program is designed to evaluate the potential for REL-1017 as a rapid-acting, oral, once-daily antidepressant treatment.\nAbout Relmada Therapeutics, Inc. \nRelmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Relmada's experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada's lead program, REL-1017, is a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 is in late-stage development as an adjunctive treatment for MDD in adults. Learn more at www.relmada.com.\nForward-Looking Statements\nThe Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf. This press release contains statements which constitute \"forward-looking statements\" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any statement that is no...